


PRODUCT INFORMATION



CV-6209-d₅
Item No. 9002895

Formal Name: 2-(2-acetyl-6-methoxy-3,9-dioxo-4,8-dioxo-2,10-diazaoctacos-1-yl)-1-ethyl-1,1,2,2,2-d₅-pyridinium, monochloride
MF: C₃₄H₅₅D₅N₃O₆ • Cl
FW: 647.4
Chemical Purity: ≥95% (CV-6209)
Deuterium Incorporation: ≥99% deuterated forms (d₁-d₅); ≤1% d₀
UV/Vis.: λ_{max}: 266 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

CV-6209-d₅ contains five deuterium atoms at the 1, 1, 2, 2, and 2 positions of the ethyl pyridinium moiety. It is intended for use as an internal standard for the quantification of CV-6209 (Item No. 15955) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated versus unlabeled).

CV-6209-d₅ is supplied as a crystalline solid. A stock solution may be made by dissolving the CV-6209-d₅ in the solvent of choice. CV-6209-d₅ is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide, which should be purged with an inert gas. The solubility of CV-6209-d₅ in these solvents is approximately 30 mg/ml.

Description

CV-6209 is a potent antagonist of the platelet-activating factor (PAF) receptor, inhibiting aggregation of rabbit and human platelets induced by PAF with IC₅₀ values of 75 and 170 nM, respectively.¹ It has little action on platelet aggregation induced by arachidonic acid, ADP, or collagen.¹ CV-6209 is bioavailable, as it prevents PAF-induced hypotension in rats, while not blocking hypotension triggered by arachidonic acid (Item No. 90010), histamine, bradykinin (Item No. 15539), or isoproterenol (Item No. 15592).¹ CV-6209 is used to study the role of PAF receptor signaling *in vitro* and *in vivo*.^{2,3}

References

1. Terashita, Z., Imura, Y., Takatani, M., *et al.* CV-6209, a highly potent antagonist of platelet activating factor *in vitro* and *in vivo*. *J. Pharmacol. Exp. Ther.* **242**(1), 263-268 (1987).
2. Leong, H.S., Mahesh, B.M., Day, J.R., *et al.* Vimentin autoantibodies induce platelet activation and formation of platelet-leukocyte conjugates *via* platelet-activating factor. *J. Leukoc. Biol.* **83**(2), 263-271 (2008).
3. Musio, S., Pedotti, P., Mantegazza, R., *et al.* Anaphylaxis to a self-peptide in the absence of mast cells or histamine. *Lab. Invest.* **89**(4), 398-405 (2009).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 05/01/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM